[go: up one dir, main page]

SG11201909689TA - Method and system for monitoring a diabetes treatment plan - Google Patents

Method and system for monitoring a diabetes treatment plan

Info

Publication number
SG11201909689TA
SG11201909689TA SG11201909689TA SG11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA
Authority
SG
Singapore
Prior art keywords
alc
patient
predicted
international
monitoring
Prior art date
Application number
Other languages
English (en)
Inventor
Sidney Soong-Ling Chan
Original Assignee
Chan Sidney Soong Ling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chan Sidney Soong Ling filed Critical Chan Sidney Soong Ling
Publication of SG11201909689TA publication Critical patent/SG11201909689TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7275Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4836Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/48Other medical applications
    • A61B5/4848Monitoring or testing the effects of treatment, e.g. of medication
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235Details of waveform analysis
    • A61B5/7246Details of waveform analysis using correlation, e.g. template matching or determination of similarity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/72Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271Specific aspects of physiological measurement analysis
    • A61B5/7282Event detection, e.g. detecting unique waveforms indicative of a medical condition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/74Details of notification to user or communication with user or patient; User input means
    • A61B5/746Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06QINFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00Commerce
    • G06Q30/06Buying, selling or leasing transactions
    • G06Q30/0601Electronic shopping [e-shopping]
    • G06Q30/0631Recommending goods or services
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Psychiatry (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Business, Economics & Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Economics (AREA)
  • Marketing (AREA)
  • Strategic Management (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
SG11201909689T 2017-06-20 2017-06-20 Method and system for monitoring a diabetes treatment plan SG11201909689TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2017/050753 WO2018232487A1 (fr) 2017-06-20 2017-06-20 Procédé et système de surveillance d'un plan de traitement du diabète à

Publications (1)

Publication Number Publication Date
SG11201909689TA true SG11201909689TA (en) 2019-11-28

Family

ID=64736237

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909689T SG11201909689TA (en) 2017-06-20 2017-06-20 Method and system for monitoring a diabetes treatment plan

Country Status (6)

Country Link
US (1) US11793471B2 (fr)
EP (1) EP3642789A4 (fr)
AU (1) AU2017420200A1 (fr)
CA (1) CA3064598A1 (fr)
SG (1) SG11201909689TA (fr)
WO (1) WO2018232487A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3839963A1 (fr) * 2019-12-20 2021-06-23 Digital Diabetes Analytics Sweden AB Système d'analyse du diabète et procédé en relation avec le système
JP7471094B2 (ja) * 2020-01-30 2024-04-19 キヤノンメディカルシステムズ株式会社 学習支援装置及び方法
WO2022050992A1 (fr) * 2020-09-02 2022-03-10 Twin Health, Inc. Surveillance virtuelle des taux de glucose chez un patient faisant appel à une technologie d'apprentissage machine et à une technologie de jumeau numérique
US20220088303A1 (en) * 2020-09-21 2022-03-24 Insulet Corporation Techniques for determining automated insulin delivery dosages
CN113876320B (zh) * 2021-09-29 2024-06-25 天津用恒医疗科技有限公司 血红蛋白浓度确定方法、装置、电子设备和存储介质
WO2024211880A2 (fr) * 2023-04-07 2024-10-10 Bigfoot Biomedical, Inc. Procédé de gestion pour une thérapie à l'insuline à l'aide de voies d'apprentissage par renforcement et d'augmentation de thérapie
WO2024259265A2 (fr) * 2023-06-14 2024-12-19 Arizona Board Of Regents On Behalf Of Arizona State University Systèmes et procédés de modélisation et de simulation de réponse glycémique pour des interventions sur le style de vie comportemental

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI112545B (fi) 1997-05-30 2003-12-15 Nokia Corp Menetelmä ja järjestelmä potilaan veren glykosyloidun hemoglobiinikomponentin tason ennustamiseksi
US6277071B1 (en) 1999-06-25 2001-08-21 Delphi Health Systems, Inc. Chronic disease monitor
PL198154B1 (pl) * 2000-03-29 2008-05-30 Univ Virginia Sposób kontroli HbA₁c pacjenta w oparciu o dane stężenia glukozy we krwi, sposób oceny hipoglikemii u pacjenta i urządzenie do kontroli cukrzycy u pacjenta
ATE392178T1 (de) * 2000-08-18 2008-05-15 Animas Technologies Llc Vorrichtung zum vorhersagen von hypoglyecemiefällen
ES2456068T3 (es) 2002-08-13 2014-04-21 University Of Virginia Patent Foundation Método, sistema y producto de programa informático para el procesamiento de datos de auto-supervisión de glucemia (SMBG) para mejorar la autogestión diabética
US7824333B2 (en) * 2006-03-31 2010-11-02 Lifescan, Inc. Diabetes management methods and systems
US20100145174A1 (en) * 2008-02-12 2010-06-10 Alferness Clifton A System And Method For Providing A Personalized Tool For Estimating Glycated Hemoglobin
US20100198021A1 (en) 2008-02-12 2010-08-05 Alferness Clifton A Computer-implemented method for providing a tunable personalized tool for estimating glycated hemoglobin
US8924159B2 (en) * 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8591410B2 (en) * 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US20100330598A1 (en) 2009-06-26 2010-12-30 Roche Diagnostics Operations, Inc. METHOD, SYSTEM, AND COMPUTER PROGRAM PRODUCT FOR PROVIDING BOTH AN ESTIMATED TRUE MEAN BLOOD GLUCOSE VALUE AND ESTIMATED GLYCATED HEMOGLOBIN (HbA1C) VALUE FROM STRUCTURED SPOT MEASUREMENTS OF BLOOD GLUCOSE
US20120253840A1 (en) * 2009-12-21 2012-10-04 Stc.Unm System and methods for estimating hba1c, treatment response, and hypoglycemia risk using self-monitoring of blood glucose data
ES2962508T3 (es) 2011-01-31 2024-03-19 Hoffmann La Roche Visualización de valores biológicos
JP5997453B2 (ja) * 2011-04-25 2016-09-28 アークレイ株式会社 情報処理装置およびユーザ端末
AU2014218785A1 (en) 2013-02-21 2015-09-10 University Of Virginia Patent Foundation Tracking changes in average glycemia in diabetics
CA3027019C (fr) 2015-06-08 2023-10-03 University Of Virginia Patent Foundation Systeme et procede de suivi des changements de glycemie moyenne chez des diabetiques
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor

Also Published As

Publication number Publication date
AU2017420200A1 (en) 2020-01-16
US20200121257A1 (en) 2020-04-23
EP3642789A4 (fr) 2021-01-27
CA3064598A1 (fr) 2018-12-27
EP3642789A1 (fr) 2020-04-29
WO2018232487A1 (fr) 2018-12-27
US11793471B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
SG11201909689TA (en) Method and system for monitoring a diabetes treatment plan
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201810221YA (en) Fidelity estimation for quantum computing systems
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201900752PA (en) Cybersecurity vulnerability management system and method
SG11201808475XA (en) Method and apparatus for providing a pharmacokinetic drug dosing regiment
SG11201804643PA (en) Indicator device
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201407508RA (en) Encoding and decoding based on blending of sequences of samples along time
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201407459QA (en) System and method for predicting the immunogenicity of a peptide
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201408261UA (en) Syringe
SG11201407860PA (en) Exendin-4 peptide analogues
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201407803TA (en) Nmr measurements of glyca
SG11201809605PA (en) Compositions for and method of treating acid-base disorders
SG11201807719SA (en) Use of clinical parameters for the prediction of sirs
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201408808WA (en) Method and system for treatment of biological tissue
SG11201807306XA (en) Uniqueness level for anonymized datasets
SG11201811550XA (en) Demand prediction for time-expiring inventory
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201809749VA (en) Computer systems and methods for implementing in-memory data structures